EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Effects of intravenous magnesium sulfate on electrocardiographic parameters in women with preeclampsia

Seyyed Mahdi Zia Ziabari, Aida Najafian, Vahedi Hojat Sheikh Motahar, Reza Safaei, Taraneh Taghavi, Nazanin Noori Roodsari

Middle East Journal of Noncommunicable Diseases · 2026

DOI: 10.66224/mejncd.1.2.20 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Middle East Journal of Noncommunicable Diseases, 2026. Verfasst von Seyyed Mahdi Zia Ziabari und 5 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Reduction of the mortality rate among pregnant women is one of the indicators of growth and development among countries, and magnesium sulfate is widely used as an important drug in the prevention of eclamptic seizures. This study aimed to evaluate the effect of intravenous magnesium sulfate on electrocardiographic parameters in patients with preeclampsia.

Method

This cross‑sectional study was performed on 45 pregnant women with preeclampsia who were hospitalized between 2020 and 2021. Inclusion criteria were a diagnosis of preeclampsia, and exclusion criteria were suffering from renal failure, calcium-potassium disorders, and baseline abnormalities in the patient's ECG before administering magnesium sulfate. A loading dose of magnesium sulfate diluted in normal saline was infused. A standard electrocardiogram was recorded before the infusion, one hour after the loading dose, and 4 hours after the start of the maintenance infusion. Heart rate and ECG parameters, including P‑wave duration, PR interval, QRS duration, QTc interval, and T‑wave axis, were assessed.

Results

Significant differences were not observed over time in P‑wave amplitude (p= 0.310), PR interval (p= 0.957), QRS duration (p= 0.999), QTc interval (p= 0.144), T‑wave amplitude (p= 0.614), and heart rate (p= 0.405).

Conclusion

Intravenous magnesium sulfate in preeclamptic patients was not associated with observable alterations in specific electrocardiographic parameters. These results suggest that further studies with a larger sample size are recommended to confirm the cardiovascular safety profile of magnesium sulfate in pregnancy.

Zitieren

APA

Ziabari, S. M. Z., Najafian, A., Motahar, V. H. S., Safaei, R., Taghavi, T., & Roodsari, N. N. (2026). Effects of intravenous magnesium sulfate on electrocardiographic parameters in women with preeclampsia. Middle East Journal of Noncommunicable Diseases. https://doi.org/10.66224/mejncd.1.2.20

Vancouver

Ziabari SMZ, Najafian A, Motahar VHS, Safaei R, Taghavi T, Roodsari NN. Effects of intravenous magnesium sulfate on electrocardiographic parameters in women with preeclampsia. Middle East Journal of Noncommunicable Diseases. 2026. doi:10.66224/mejncd.1.2.20

BibTeX
@article{Ziabari2026,
  author = {Ziabari, Seyyed Mahdi Zia and Najafian, Aida and Motahar, Vahedi Hojat Sheikh and Safaei, Reza and Taghavi, Taraneh and Roodsari, Nazanin Noori},
  title = {Effects of intravenous magnesium sulfate on electrocardiographic parameters in women with preeclampsia},
  journal = {Middle East Journal of Noncommunicable Diseases},
  year = {2026},
  doi = {10.66224/mejncd.1.2.20}
}
Kostenlos starten →